Thirty-seven-year-old Nupur Lalvani, who has been living with Type 1 diabetes since the age of eight, was dependent on ...

Even though the stock is down notably from the peak price it hit last year, it's still doing far better than in the pre-approval days. Competitors are biting at its heels in the weight loss segment, ...

Novo Nordisk has awarded a 50 million kroner ($7.6M) grant to the University of Copenhagen to develop less processed ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ ...

Stock futures edged higher despite the trade war between the world's largest economies spiraled further Friday, with China lifting tariffs on the U.S . to 125% and scoffing that further U.S. levies ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil. | Looking to ...

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 billion) in Brazil to increase production at its facility in Minas Gerais ...

HYDERABAD (Reuters) - Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better compete with rival Eli Lilly in the populous nation, two ...

HYDERABAD, April 7 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better compete with ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... and healthcare segments and the real estate and energy areas. Reuters reported that analysts have been turning ...